✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
AT7519 is an investigational drug.
There have been 5 clinical trials for AT7519. The most recent clinical trial was a Phase 2 trial, which was initiated on July 24th 2012.
The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Mantle-Cell, and Leukemia, Lymphoid. The leading clinical trial sponsors are NCIC Clinical Trials Group, Astex Pharmaceuticals, and Astex Pharmaceuticals, Inc.
Recent Clinical Trials for AT7519
|Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery||National Cancer Institute (NCI)||Phase 1|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma||Astex Pharmaceuticals||Phase 2|
|A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma||Astex Pharmaceuticals, Inc.||Phase 2|